Background: Adrenocortical carcinoma is a rare and aggressive malignancy. Patients usually present early with manifestation of abnormal hormone secretion. However, adrenocortical carcinoma can also be nonfunctioning, and such patients present late with a mass effect or distant metastases.
Case Presentation: We herein report a case of a 30-year-old Sri-Lankan woman who presented with a 3-month history of left flank pain associated with nausea, vomiting, and weight loss. Imaging revealed a large left upper quadrant mass with a 1.8-cm left lung nodule. The differential diagnoses included a left adrenal mass, left upper pole renal mass, and retroperitoneal sarcoma. A functional adrenal work-up revealed no abnormal findings. Surgical excision of the mass was uneventful with no postoperative complications. Pathological analysis revealed a nonfunctioning adrenocortical carcinoma measuring 16 × 14 × 10 cm. To our knowledge, a mass of this size is among the largest nonfunctioning adrenocortical carcinomas reported in the published literature. The investigations and approach to treatment were consistent with those in the published literature.
Conclusion: Large nonfunctioning adrenocortical carcinomas pose a diagnostic and therapeutic challenge, and most are diagnosed at a late stage. Appropriate imaging and functional work-up of the mass are vital before treatment. Surgical excision is safe, even for large adrenocortical carcinomas; excision in patients with advanced disease has been shown to have the best outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223740 | PMC |
| http://dx.doi.org/10.1186/1756-0500-7-769 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Single Center Experience of Special Cases: Isolated Adrenal Myelolipoma and Adrenocortical Adenoma with Myelolipomatous Component.
Arch Esp Urol
November 2024
Department of Urology, Gazi University Faculty of Medicine, 06560 Ankara, Turkey.
Objective: Isolated adrenal myelolipoma (IAM) is an uncommon, nonfunctioning tumour of the adrenal gland, primarily composed of adipose tissue and hematopoietic trilinear cells. The etiopathogenesis and clinical relevance of this neoplasm remain poorly understood. However, similar myelolipomatous alterations can also occur within adrenocortical adenomas.
View Article and Find Full Text PDFFrench AFU Cancer Committee Guidelines - Update 2024-2026 : Assessment of an adrenal incidentaloma and oncological management.
Fr J Urol
November 2024
Comité de Cancérologie de l'Association française d'urologie, Groupe organes génitaux externes, Maison de l'Urologie, 11, rue Viète, 75017 Paris, France; Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitié-Salpêtrière Hospital, 75013 Paris, France.
Introduction: The aim of this publication is to review the initial management procedure for adrenal incidentalomas, and where appropriate, to establish a carcinological management procedure for malignant adrenal tumours.
Materials And Methods: The multidisciplinary working group updated the CCAFU 2022 recommendations for the carcinological management of adrenal incidentalomas on the basis of a comprehensive PubMed review of the literature.
Results: Although the majority of adrenal masses are benign and nonfunctional, it is important to investigate them because of their serious endocrine potential, and because of certain cancers.
Adrenocortical tumors and hereditary syndromes.
Expert Rev Endocrinol Metab
November 2024
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Introduction: Adrenocortical tumors (ACTs) are frequently encountered in clinical practice. They vary in clinical and biological characteristics from nonfunctional to life threatening hormone excess, from benign to highly aggressive malignant tumors. Most ACTs appear to be benign and nonfunctioning.
View Article and Find Full Text PDFPartial adrenalectomy by the posterior retroperitoneoscopic approach: A single institution series of 766 consecutive procedures.
World J Surg
November 2024
Department of Surgery and Center of Minimally Invasive Surgery, Evang. Kliniken Essen-Mitte, Academic Teaching Hospital of the University of Duisburg-Essen, Essen, Germany.
Background: Partial adrenalectomy (PA), as an alternative to total adrenalectomy in selected cases, allows for the preservation of adrenocortical function, especially in hereditary and/or bilateral diseases. In this study, we analyze our experience in posterior retroperitoneoscopic PA (PRPA) and its impact on adrenocortical function.
Patients And Methods: From January 2010 to December 2023, 709 PRPAs were performed on 766 adrenal glands in a total of 697 patients (421F; 276M; and mean age 49.
Presentation and management of patients with adrenal masses: a large tertiary centre experience.
Eur J Endocrinol
October 2024
Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham B152TT, United Kingdom.
Article Synopsis
- - The study analyzed adrenal masses in 1,397 patients at a tertiary care center from 1998 to 2022, revealing that most cases were found incidentally, with a median mass size of 2.9 cm and common diagnoses including adrenocortical adenoma, phaeochromocytoma, and adrenocortical carcinoma.
- - Following the 2016 European guidelines on adrenal incidentalomas, there was a notable decrease in the number of adrenalectomies (6.1% to 4.5%) and a significant increase in the discharge rate for patients with benign adrenal masses (4.4% to 25.3%).
- - The findings suggest that implementing these guidelines has
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!